VERU - Veru Inc.
| Previous Close | 2.4000 |
| Open | 2.4000 |
| Bid | 2.3600 x 1200 |
| Ask | 2.4000 x 1200 |
| Day's Range | 2.3500 - 2.4400 |
| 52 Week Range | 1.1800 - 2.4900 |
| Volume | 245,260 |
| Avg. Volume | 121,750 |
| Market Cap | 157M |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2770 |
| Earnings Date | Dec 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2014-04-28 |
| 1y Target Est | 7.38 |
- GlobeNewswire
Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%
--Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Men with Metastatic.
- GlobeNewswire
Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th
Veru Inc. (VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2019 fourth quarter and full year ended September 30, 2019 on Thursday, December 12, 2019, before the market opens. Veru’s management will host a conference call that same day at 8 a.m. Eastern Time to review the Company’s performance and answer questions. Interested investors may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call.
- Simply Wall St.
Veru (NASDAQ:VERU) Shareholders Have Enjoyed A 93% Share Price Gain
While Veru Inc. (NASDAQ:VERU) shareholders are probably generally happy, the stock hasn't had particularly good run...
- GlobeNewswire
Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes
Veru Inc. (VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and supportive care, today announced that it has achieved full enrollment for its Phase 2 clinical study of zuclomiphene citrate, a nonsteroidal oral estrogen receptor agonist for the treatment of androgen deprivation hormone therapy (ADT) induced hot flashes in men who have advanced prostate cancer. “Our proprietary zuclomiphene citrate product has the potential to be the first FDA-approved treatment for this most common and debilitating side effect of ADT as hot flashes occur in up to 80% of men,”* said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru.
- Simply Wall St.
Does Veru (NASDAQ:VERU) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- GlobeNewswire
Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York
Morgan Stanley 17th Annual Global Healthcare Conference, on September 11, 2019, at the Grand Hyatt New York Hotel. Veru will participate in one on one meetings with investors. Oppenheimer Fall Summit, on September 23-24, 2019, at the Parker New York Hotel. Veru will participate in one on one meetings with investors. Cantor Fitzgerald Global Healthcare Conference on October 2, 2019, at 3:35 p.m. ET, at the InterContinental New York Barclay Hotel. In addition to one on one meetings with investors, Veru will be making a formal presentation. A webcast of the Cantor Fitzgerald presentation will be available at www.verupharma.com. Listeners are encouraged to visit the web site at least 10 minutes prior to the start of the presentation to register, download and install any necessary software. The presentation will be archived and accessible on the web site for at least 90 days.
- GlobeNewswire
Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month
Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that it has been invited by NASDAQ to ring the closing bell on September 4, 2019, to kick off National Prostate Cancer Awareness Month. Veru’s Chairman, President and Chief Executive Officer, Dr. Mitchell Steiner, will be joined by company management and other guests at the closing bell ceremony. “September is National Prostate Cancer Awareness Month. This is a time that we reflect on the progress being made in the management of prostate cancer. Patients with advanced prostate cancer are becoming resistant to the novel androgen blocking drugs that came on the scene, like abiraterone and enzalutamide, several years ago and their cancer is now advancing and progressing.
- GlobeNewswire
Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter
Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot.
- GlobeNewswire
Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th
Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals, today announced that on Thursday, August 8, 2019, the Company will report financial results for its fiscal 2019 third quarter ended June 30, 2019, before the market opens. Veru’s management will host a conference call that same day at 8 a.m. Eastern Time to review the Company’s performance and to answer questions. In addition, investors may access a replay of the conference call the same day beginning at approximately noon Eastern Time by dialing 877-344-7529 for U.S. callers, or 412-317-0088 from outside the U.S., passcode 10133960. The replay will be available for one week, after which, the recording will be available via the Company’s website at https://verupharma.com/investors.
- Benzinga
Biotech Stock On The Radar: Veru, A Catalyst-Rich Biopharma
Thinly traded micro-cap Veru Inc (NASDAQ: VERU) has added about 62% year to date — a commendable performance compared to the broader biotech sector. After peaking at just under $10 and forming a double-top in late 2013, Veru stock was in a free fall for the next two years, selling off steeply. Veru's origins can be traced back to the Wisconsin Pharmacal Company, which was incorporated in 1971 and marketed specialty chemical and branded consumer products.
- Simply Wall St.
What Kind Of Shareholder Appears On The Veru Inc.'s (NASDAQ:VERU) Shareholder Register?
The big shareholder groups in Veru Inc. (NASDAQ:VERU) have power over the company. Generally speaking, as a company...
- GlobeNewswire
Veru Announces Dismissal of Lawsuit; Prevails on All Counts in Motion for Summary Judgment
Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced the dismissal of litigation against the Company and certain of its officers and directors. In response to the Company’s acquisition of Aspen Park Pharmaceuticals, Inc., two purported derivative and class action lawsuits were filed against the Company and certain of its officers and directors in the Circuit Court of Cook County, Illinois, on October 21, 2016 and November 7, 2016, respectively. On March 31, 2017, these two lawsuits were consolidated and on November 30, 2018, plaintiffs filed an amended consolidated complaint. The parties filed cross-motions for summary judgment on the amended consolidated complaint on April 15, 2019.
- Zacks
Options Traders Expect Huge Moves in Veru (VERU) Stock
Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.
- GlobeNewswire
Veru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia
Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that the Company concluded its pre-New Drug Application ("NDA") meetings with the U.S. Food and Drug Administration ("FDA") for TADFIN® (tadalafil 5mg and finasteride 5mg combination) formulation for the treatment of benign prostatic hyperplasia (BPH). The purpose of the meeting was to discuss the proposed NDA and to confirm the clinical, non-clinical, and chemistry, manufacturing and controls (CMC) requirements for the Company's NDA submission utilizing the FDA expedited 505(b)(2) regulatory pathway. Veru submitted a pre-NDA briefing document to the FDA that outlined the Company's preliminary data package being prepared for the NDA submission, including bioequivalence and bioavailability clinical study results, CMC and other regulatory elements for a 505(b)(2) submission.
- GlobeNewswire
Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA
Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that it has added to its robust prostate cancer drug development pipeline, a proprietary biologic drug candidate, VERU-100, for the treatment of hormone sensitive advanced prostate cancer, an established multi-billion-dollar global market. VERU-100 was internally developed in collaboration with Drug Delivery Experts, LLC of San Diego, California (DDE Labs). “The target product profile for VERU-100 is most compelling having a number of advantages over currently available androgen deprivation therapies.
- GlobeNewswire
Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th
Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that the Company will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 2:00 p.m. ET at the Grand Hyatt New York hotel. Veru Inc. is an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. The Veru prostate cancer pipeline includes zuclomiphene citrate (also known as VERU-944, cis-clomiphene) and VERU-111 (bisindole). Zuclomiphene citrate is an estrogen receptor agonist being evaluated in a Phase 2 trial to treat hot flashes, a common side effect caused by hormone treatment for men with advanced prostate cancer.
- Simply Wall St.
Is Veru Inc.'s (NASDAQ:VERU) CEO Overpaid Relative To Its Peers?
Mitch Steiner has been the CEO of Veru Inc. (NASDAQ:VERU) since 2016. This analysis aims first to contrast CEO...
- GlobeNewswire
Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results
-- Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising –-- Strong Financial Results for Q2 and YTD FY 2019 ---- Company to Host Investor.
- GlobeNewswire
Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th
Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals, today announced that on Wednesday, May 15, 2019, the Company will report financial results for its fiscal 2019 second quarter ended March 31, 2019, before the market opens. Veru’s management will host a conference call that same day at 8 a.m. Eastern Time to review the Company’s performance and to answer questions. Interested investors may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call. In addition, investors may access a replay of the conference call the same day beginning at approximately noon Eastern Time by dialing 877-344-7529 for US callers, or 412-317-0088 from outside the U.S., passcode 10130716. The replay will be available for one week, after which, the recording will be available via the company’s website at https://verupharma.com/investors.
- Zacks
Veru (VERU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Veru (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Introducing Veru (NASDAQ:VERU), The Stock That Tanked 81%
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't w...
- GlobeNewswire
Veru to Participate in Two Investor Conferences in March
Barclays Global Healthcare Conference on March 12–14, 2019 at the Loews Miami Beach Hotel. Veru will meet with investors. There will be no webcast. Oppenheimer 29th Annual Healthcare Conference. Veru will present at 10:20 a.m. ET on Wednesday, March 20, 2019 at the Westin New York Grand Central, in New York City. Veru Inc. is an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals. The Veru prostate cancer pipeline includes zuclomiphene citrate (also known as VERU-944, cis-clomiphene) and VERU-111 (bisindole). Zuclomiphene citrate is an estrogen receptor agonist being evaluated in a Phase 2 trial to treat hot flashes, a common side effect caused by hormone treatment for men with advanced prostate cancer.
- Simply Wall St.
Have Insiders Been Buying Veru Inc. (NASDAQ:VERU) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examplesRead More...
- GlobeNewswire
Veru Reports Strong Fiscal 2019 First Quarter Financial Results
-- Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling -- -- Company to Host Investor.
- GlobeNewswire
Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium
Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced that four presentations relating to Veru drug candidates are being given at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium being held February 14-16, 2019 at the Moscone West Building in San Francisco, California. Three of the presentations will be about VERU-111, our first-in-class selective oral alpha and beta tubulin inhibitor, which is in a Phase1b/Phase 2 clinical study in 5 clinical sites in the United States. The Phase 1b/2 addresses the large and growing unmet medical need to provide therapies for men who have metastatic castration resistant prostate cancer and who have also become resistant to novel androgen blocking agents (enzalutamide or abiraterone). There are currently no FDA approved drugs approved for this indication.
